Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based ...

Bengaluru: Merck KGaA, a science and technology company, is in late-stage negotiations to buy SpringWorks Therapeutics, a US ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...

German healthcare and materials group Merck KGaA has struck a deal, it said on Monday, to acquire U.S. biotech company ...

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...